

# SB1317 (TG-02)

<b>ALTERNATE NAME:</b>	(16E)-14-methyl-20-oxa-5,7,14,27-tetraza-tetracyclo[19.3.1.12.6.18,12]heptacos-1(25),2(27),3,5,8,10,12(26),16,21,23-decaene Zotiraciclib
<b>CATALOG #:</b>	B3218-5    5 mg B3218-25   25 mg
<b>MOLECULAR FORMULA:</b>	C <sub>23</sub> H <sub>24</sub> N <sub>4</sub> O
<b>MOLECULAR WEIGHT:</b>	372.46
<b>CAS NUMBER:</b>	1204918-72-8
<b>APPEARANCE:</b>	Crystalline solid
<b>PURITY:</b>	≥98%
<b>SOLUBILITY:</b>	>20 mg/ml DMSO
<b>DESCRIPTION:</b>	SB1317 is a potent inhibitor of CDK2, JAK2, and FLT3 with IC <sub>50</sub> of 13, 73, and 56 nM, respectively. SB1317 may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9).
<b>STORAGE TEMPERATURE:</b>	-20°C. Protect from light
<b>HANDLING:</b>	Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
<b>RELATED PRODUCTS:</b>	Dinaciclib (9537) AZD1480 (2315) CEP-33779 (B2473) CCT-241736 (B2370) Tandutinib (2024)
<b>DISCLAIMER:</b>	<b><i>FOR RESEARCH USE ONLY! Not to be used on humans.</i></b>